DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vaniprevir
Vaniprevir
Caracterización Molecular Del Perfil De Resistencias Del Virus De La
Synthesis and Evaluation of New HCV NS3/4A Protease Inhibitors
ABT-450/R (Abbott) – GS-9451 (Gilead) • Second Generation (Pan-Genotype, High Barrier to Resistance) – MK-5172 (Merck) – ACH-2684 (Achillion)
Documents Numérisés Par Onetouch
Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize With
Mechanisms of Substrate Recognition by HCV NS3/4A Protease Provide Insights Into Drug Resistance: a Dissertation
Stembook 2018.Pdf
HEPATITIS C MEDICINES Technology and Market Landscape
Hepatitis C Viral Replication Complex
Research 1..51
Repurposing of FDA Approved Drugs
Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance
WO 2015/030853 Al 5 March 2015 (05.03.2015) P O P C T
A Study of Vaniprevir (MK-7009)
Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant
Technology and Market Landscape for Hepatitis C Medicines
Molecular Docking and Molecular Dynamic Simulation
The Molecular Basis of Drug Resistance Against Hepatitis C Virus NS3/4A Protease Inhibitors
Top View
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-Cov-2 in Vitro
Drug Resistance Against HCV NS3/4A Inhibitors Is Defined by the Balance of Substrate Recognition Versus Inhibitor Binding
Japanese Hepatitis C Market Forecast: Methodology and Implications
Emerging Therapeutic Options in Hepatitis C Virus Infection
Vaniprevir Plus Peginterferon Alfa-2B and Ribavirin in Treatment-Naive Japanese Patients with Hepatitis C Virus Genotype 1 Infection: a Randomized Phase III Study
Vaniprevir Plus Peginterferon Alfa-2B and Ribavirin in Treatment-Experienced Japanese Patients with Hepatitis C Virus Genotype 1 (Gt1b) Infection: Phase 3 Studies
Report on the Deliberation Results November 16, 2016
Identification of SARS-Cov-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors
201917Orig1s000
Therapy Implications of Hepatitis C Virus Genetic Diversity
From Acyclovir to Direct-Acting Antiviral Agents (Daas) for Hepatitis C
Targeting Allosteric Pockets of SARS-Cov-2 Main Protease Mpro
Remdesivir from Wikipedia, the Free Encyclopedia
Synthesis and Kinetic Analysis of HCV NS3/4A Protease Inhibitors
A Phase 2B Study of MK-7009 (Vaniprevir) in Patients with Genotype 1 HCV Infection Who Have Failed Previous Pegylated Interferon and Ribavirin Treatment
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Interferon-Based Combination Treatment for Chronic Hepatitis C in the Era of Direct Acting Antivirals
Future Perspectives in the Treatment of Chronic Hepatitis C
Revision of Precautions Hepatitis C Direct Acting Antivirals Asunaprevir, Simeprevir Sodium, Telaprevir, Vaniprevir
Us 2019 / 0111068 A1
HIV, HCV, TB: 2012 Pipeline Report, TAG and I-Base
Hepatitis C Virus: Structural Insights Into Protease Inhibitor Efficacy and Drug Resistance: a Dissertation
OMBITASVIR, PARITAPREVIR/RITONAVIR Co‐Formulated Tablet with Or Without DASABUVIR
HCV Diagnosis and Monitoring in the Era of Direct-Acting Antiviral Agents
2011 Pipeline Report Second Edition
The Importance of Resistance to Direct Antiviral Drugs in HCV Infection in Clinical Practice